A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer

Overview

This trial is going to evaluate the advantage of D2 radical gastrectomy plus 14v lymph node dissection in 3-year survival rates of advanced gastric cancers.

Full Title of Study: “Randomized Controlled Trial to Evaluate Mesenteric Vein (14V) Lymphadenectomy for Gastric Cancer”

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: November 2016

Detailed Description

Radical surgery is still the only possible way to cure gastric cancer. In Japan, South Korea and other countries, due to the popularity of screening and Improved surgical procedures, there has been great improvement in overall survival. Standard D2 Gastrectomy has been the standard operation for advanced gastric cancer. However, there is no unanimous consensus whether Standard D2 Gastrectomy plus 14v lymph node dissection is needed.Till now, it is difficult to stage the 14V lymph node as regional lymph nodes metastasis or distant metastasis. And it is urgent to explore the necessity of 14v lymph node dissection in advanced gastric cancer.So a prospective randomized controlled study will to carry out to evaluate the effects of D2 radical gastrectomy plus 14v lymph node dissection compared with D2 radical gastrectomy.

Interventions

  • Procedure: Dissection of the Superior Mesenteric Vein Lymph Node
    • 14v lymph node dissection

Arms, Groups and Cohorts

  • Group A
    • D2 Radical Gastrectomy Adding Dissection of the Superior Mesenteric Vein Lymph Node
  • Group B
    • D2 Radical Gastrectomy

Clinical Trial Outcome Measures

Primary Measures

  • overall survival
    • Time Frame: 3 years
    • Overall survival (OS) was defined as the length of time from the date of randomization to the date of death of various reasons.

Secondary Measures

  • disease free survival
    • Time Frame: 3 years
    • Disease free survival (DFS) was defined as the length of time from the date of randomization to the date of first documentation of relapse of gastric cancer or any other type of cancer or death.

Participating in This Clinical Trial

Inclusion Criteria

  • Curative D2 or D2+ operation had been performed; – Physical condition and organ function allows to tolerable abdominal surgery; – Willing and able to comply with the program during the study period; – Aged 18 to 70 years, preoperative gastric cancer patients with pathologically confirmed; – With more than a 6-month life expectancy; – No other serious concomitant diseases; – No adjuvant chemotherapy before recurrence; – Karnofsky performance status scale ≥ 60; – All patients accept 6 cycles XELOX chemotherapy regimen Exclusion Criteria:

  • Pregnancy or breast feeding; – Women of childbearing age do not take contraceptive measures; – Organ transplantation patients need immunosuppressive therapy; – Five years after the trial begin,other malignant tumor occur; – While using other experimental drug or other clinical trials are being; – Can not take oral medications; – Mentally disordered; – Severe recurrent infections were not controlled or with other serious concomitant diseases;

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Tianjin Medical University Cancer Institute and Hospital
  • Collaborator
    • The First Affiliated Hospital with Nanjing Medical University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Han Liang, Master, Principal Investigator, Tianjin Medical University Cancer Hospital
  • Overall Contact(s)
    • Han Liang, Master, 086-022-23340123, tjlianghan@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.